Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring

Journal of Infectious Diseases

Volumn 167, Issue 1, 1993, Pages 173-179

  Bertino, Joseph S ^a   Booker, Leigh Ann ^a,b,c   Franck, Patrick A ^a   Jenkins, Paul L ^a   Franck, Kevin R ^a   Nafziger, Anne N ^a  

^a BASSETT RESEARCH INSTITUTE   (United States)

^b ST LUKE S HOSPITAL   (United States)

^c ALBANY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; CARBENICILLIN; CEPHALOSPORIN; CLINDAMYCIN; FUROSEMIDE; GENTAMICIN; PIPERACILLIN; TICARCILLIN; TOBRAMYCIN; VANCOMYCIN;

ADULT; AGE; AGED; ARTICLE; ASCITES; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG MONITORING; FEMALE; FEVER; HUMAN; HYPOALBUMINEMIA; INTENSIVE CARE; KIDNEY DISEASE; LEUKEMIA; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; NEPHROTOXICITY; NUTRITIONAL STATUS; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SHOCK;

ADULT; AGED; ANTIBIOTICS, AMINOGLYCOSIDE; CREATININE; FEMALE; HUMAN; KIDNEY; MALE; MIDDLE AGE; MONITORING, PHYSIOLOGIC; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; RISK FACTORS; SUPPORT, NON-U.S. GOV'T;

EID: 0027475979     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/167.1.173     Document Type: Article

References (36)

1. Pancoast SJ. Aminoglycoside antibiotics in clinical usage. Med Clin North Am 1988;72:581-612.
2. Moore RD, Smith CR, Lietman PS. Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am J Med 1984;77:657-62.
3. Moore RD, Smith CR, Lietman PS. Association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis 1984;149:443-8.
4. Smith CR. Baughman KL. Edwards CQ. Rogers JF. Lietman PS. Controlled comparison of amikacin and gentamicin. N Engl J Med 1977;296:349-53.
5. Smith CR, Lipsky JJ, Laskin OL, et al. Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin. N Engl J Med 1980;302: 1106-9.
6. Moore RD, Smith CR, Lipsky JJ, Mellits ED, Lietman PS. Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med 1984;100:352-7.
7. Sawyers CL, Moore RD, Lerner SA, Smith CR. A model for predicting nephrotoxicity in patients treated with aminoglycosides. J Infect Dis 1986; 153:1062-8.
8. Eisenberg JM, Koffer H, Glick HA. et al. What is the cost ofnephrotoxicity associated with aminoglycosides? Ann Intern Med 1987;107: 900-9.
9. Holloway JJ, Smith CR, Moore RD, Feroli ER, Lietman PS. Comparative cost effectiveness of gentamicin and tobramycin. Ann Intern Med 1984;101:764-9.
10. Zaske DE, Sawchuck RJ, Gerding DN, Strate RG. Increased dosage requirements of gentamicin in burn patients. J Trauma 1976;16: 824-8.
11. Zaske DE. Cipolle RJ. Strate RJ. Gentamicin dosage requirements: wide interpatient variation in 242 surgery patients with normal renal function. Surgery 1980;87: 164-9.
12. Carr MR. Dick SP, Bordley J IV, Bertino JS Jr. Gentamicin dosing requirements in patients with acute pancreatitis. Surgery 1988; 103: 533-7.
13. Levy J, Smith AL, Koup JR, Williams-Warren J, Ramsey B. Disposition oftobramycin in patients with cystic fibrosis: a controlled study. J Pediatr 1984; 105:117-24.
14. Pancorbo S, Compty C, Hessier J. Comparison of gentamicin and tobramycin nephrotoxicity in patients receivingindividualized-pharmacokinetic dosing regimens. Biopharm Drug Dispos 1982;3:83-8.
15. Siegenthaler WE, Bonetti A, Luthy R. Aminoglycoside antibiotics in infectious diseases. an overview. Am J Med 1986;80(suppl 6B):214.
16. Zaske DE. Aminoglycosides. In: Evans WF, Schentag JJ, Jusko WJ, eds. Applied pharmacokinetics: principles of therapeutic drug monitoring. 2nd ed. Spokane, WA: Applied Therapeutics, 1986.
17. Chan GLC, Alternative dosing strategy for aminoglycosides: impact on efficacy, nephrotoxicity. and ototoxicity. DICP 1989;23:788-94.
18. Sawchuk RJ, Zaske DE. Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients. J Pharmacokinet Biopharm 1976;4: 183-95.
19. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.
20. McCabe WR, Jackson GG. Gram-negative bacteremia. I. Etiology and ecology. Arch Intern Med 1962;110:83-91.
21. Grant JP. Handbook of total parenteral nutrition. 1st ed. Philadelphia: WB Saunders, 1980: 11.
22. SAS user's guide. Statistics. Cary. NC: SAS Institute, 1985.
23. Cimino MA, Rotstein C, Slaughter RL, Emrich U. Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy. Am J Med 1987;83: 1091-7.
24. Farber BF, Moellering RC Jr. Retrospective study of the toxicity of preparations of vancomycin from 1974-1981. Antimicrob Agents Chemother 1983;23: 138-41.
25. Wade JC, Smith CR, Petty BG, et al. Cephalothin plus an arninoglycoside is more nephrotoxic than methicillin plus an aminoglycoside. Lancet 1978;2:604-6.
26. Sabra R. Branch RA. Role of sodium in protection by extended-spectrum penicillins against tobramycin-induced nephrotoxicity. Antimicrob Agents Chemother 1990;34:1020-5.
27. Hughes WT, Bodey GP, Feld R. et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990;161:381-96.
28. Appel GB. Aminoglycoside nephrotoxicity. Am J Med 1990;88(suppl 3C): 16s-20s.
29. Choice of antimicrobial agents. Med Lett Drugs Ther 1992;34:49-56.
30. Ilorvick JA, Yu VL. Antimicrobial agent therapy for Pseudomonas aeruginosa. Antimicrob Agents Chemother 1991;35:2167-72.
31. Lam YWF, Arana CJ, Shikuma LR, Rothschafer JC. The clinical utility of a published nomogram to predict aminoglycoside nephrotoxicity. JAMA 1986;255:639-42.
32. Moore RD, Smith CR, Lietman PS. Increased risk of renal dysfunction due to interaction of liver disease and aminoglycosides. Am J Med 1986;80: 1093-7.
33. Desai TK. Tsang TK. Aminoglycoside nephrotoxicity in obstructive jaundice. Am J Med 1988;85:47-50.
34. Welage LS. Walawander CA. Grasela TH Jr. A multicenter survey of risk factors for nephrotoxicity in patients with bacterial pneumonia. Clin Pharmacol Ther 1991; 49:150.
35. Colburn WA, Schentag JJ, Jusko WJ, Gibaldi M. A model for the prospective identification of the prenephrotoxic state during gentamicin therapy. J Pharmacokinet Biopharm 1978;6: 179-86.
36. Etzel JV, Nafziger AN, Bertino JS Jr. Variation in the pharmacokinetics ofgentamicin and tobramycin in patients with pleural effusions and hypo albuminemia. Antimicrob Agents Chemother 1992;36:67981.